Data show that among stage III NSCLC patients receiving chemoradiotherapy, patients with higher CD8+ tumor-infiltrating lymphocyte density in pre-treatment biopsy specimens had longer PFS and OS 48. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.